Author: Publisher:
ISBN:
Category : Cancer
Languages : en
Pages : 212
Book Description
Interpreting Clinical Data : Highlights from ASCO 1998
Author: ASCO 1998
Author: American Society of Clinical OncologyPublisher:
ISBN:
Category :
Languages : sv
Pages : 31
Book Description
American Society of Clinical Oncology 1998 Educational Book
Author: Olufunmilayo I. OlopadePublisher:
ISBN: 9780966449501
Category : Cancer
Languages : en
Pages :
Book Description
The curriculum is in two loose-leaf, three-ring binders to easily accommodate the periodic updates that are planned. The binder contains a set of more than 300 color slides with text. The curriculum will be offered to libraries and individuals with an accompanying CD-ROM, from which user can download to a diskette the slides relevant to a particular lecture of course. - p. xii.
Malignant Pleural Mesothelioma
Author: Ken O'ByrnePublisher:
ISBN: 0198529309
Category : Medical
Languages : en
Pages : 475
Book Description
This book provides health professionals and scientists with a comprehensive overview of the mesothelioma - an asbestos induced malignancy. It includes chapters on epidemology, diagnosis, histopathology, radiology, surgery, chemotherapy, immune therapy, and radiotherapy as well as the molecular biology and future therapies.
Journal of the National Cancer Institute
Author: American Society of Clinical Oncology Educational Book
Author: Michael C. PerryAmerican Society of Composites, Fourteenth International Conference Proceedings
Author: Amer Society ComposiPublisher: CRC Press
ISBN: 9781566767910
Category : Technology & Engineering
Languages : en
Pages : 1030
Book Description
Conference proceedings of the Fourteenth American Society for Composites held on the September 27-29 1999 at the Holiday Inn-1675 Conference Centre, Fairborn, Ohio.
False Hope
Author: Richard A. RettigPublisher: Oxford University Press
ISBN: 0195187768
Category : History
Languages : en
Pages : 368
Book Description
In the late 1980s, a promising new treatment for breast cancer emerged: high-dose chemotherapy with autologous bone marrow transplantation or HDC/ABMT. By the 1990s, it had burst upon the oncology scene and disseminated rapidly before having been carefully evaluated. By the time published studies showed that the procedure was ineffective, more than 30,000 women had received the treatment, shortening their lives and adding to their suffering. This book tells of the rise and demise of HDC/ABMT for metastatic and early stage breast cancer, and fully explores the story's implications, which go well beyond the immediate procedure, and beyond breast cancer, to how we in the United States evaluate other medical procedures, especially life-saving ones.It details how the factors that drove clinical use--patient demand, physician enthusiasm, media reporting, litigation, economic exploitation, and legislative and administrative mandates--converged to propel the procedure forward despite a lack of proven clinical effectiveness. It also analyzes the limited effect of technology assessments before randomized clinical trials evaluated decisively the procedure and the ramifications of this system on healthcare today.Sections of the book consider the initial conditions surrounding the emergence of the new breast cancer treatment, the drivers of clinical use, and the struggle for evidence-based medicine. A concluding section considers the significance of the story for our healthcare system.
Principles of Molecular Oncology
Author: Miguel H. BronchudPublisher: Springer Science & Business Media
ISBN: 1592596649
Category : Medical
Languages : en
Pages : 716
Book Description
At the midpoint of the 20th century, our knowledge of cancer was based on epide- ology and pathology, and treatment consisted of surgery and radiation therapy. At mid-century, Medawar and colleagues initiated the understanding of transplantation immunology, Farber described the first use of an antifolic drug to treat leukemia, and Jacobson and coworkers described the irradiation-protection effect of spleen cells. These observations opened the door to the development of chemotherapy and tra- plantation in the treatment of cancer. Despite the rapid development of these new disciplines, progress was usually based on empiric observations and clinical trials. The rapid advances in molecular biology at the end of the 20th century mark a new era in our knowledge of cancer. Molecular immunology, molecular genetics, mole- lar pharmacology, and the Human Genome Project are in the process of providing a level of understanding of cancer undreamed of in the past. Optimism is based on the firm belief that understanding at the molecular level will lead to better and earlier di- nosis, to new forms of treatment, and, most importantly, eventually to prevention of many types of cancer.
Management of Prostate Cancer
Author: Eric A. KleinPublisher: Springer Science & Business Media
ISBN: 1592597149
Category : Medical
Languages : en
Pages : 372
Book Description
Prostate cancer remains the most common malignant tumor in elderly men. The National Cancer Institute estimated 210,000 new cases of prostate cancer in 1997. There is, however, no means of documenting the true incidence of prostate cancer because of the difficulty in detecting all cases. Even using yearly rectal exams, PSA determinations, and ultrasound-guided prostate biopsies, many cases are missed. Suffice it to say that prostate cancer is a widely occurring disease in men and early detection and treatment are extremely important. When I trained in Urology under Dr. Reed Nesbit at the University of Michigan from 1956 to 1959, the diagnosis of prostate cancer was made by a rectal examination and an acid phosphatase determination. If there was a small nodule in the prostate, then an anterior-posterior X-ray of the pelvis was obtained to look for possible bony metastases. If the acid phosphatase was normal and there was no evidence ofa bony metastasis, the prostate was exposed through the perineal approach and a biopsy of the nodule was obtained and sent for frozen section to Pathology to determine if it was indeed a cancer of the prostate. If the biopsy came back positive, the surgeon then proceeded to do a radical perineal prostatectomy. In those days, we usually did eight to ten radical perineal prostatectomies yearly. Many times the nodule that was biopsied was benign, and the incision was simply closed.